Investors & Media

Corporate Profile

Kronos Bio is a clinical-stage biopharmaceutical company discovering and developing therapeutics that target the deregulated transcription that cause cancer and autoimmune diseases. Kronos Bios has a pipeline that includes a clinical-stage candidate and two preclinical-stage candidates.

Market Cap $

Minimum 15 minutes delayed. Source: LSEG